To analyze the efficacy and safety of adjuvant targeted therapy for EGFR-positive stage ⅠA invasive lung adenocarcinoma after complete resection.

All of 82 patients with lung adenocarcinoma admitted in our hospital from January, 2016 to February, 2022 were selected and divided into observation group 34 cases and control group 34 cases by propensity score matching (PSM). The observation group was treated with EGFR-TKIs before tumor recurrence and metastasis, and postoperative chemotherapy was allowed.The control group was not treated with EGFR-TKIs or only received chemotherapy before recurrence. The clinical characteristics, postoperative treatment plan and efficacy, median disease-free survival (median DFS) and safety of the above patients were sorted and analyzed.

After matching, the median follow-up time of observation group and control group were 22.43(8.57-56.39)months and 22.16(7.14-51.00)months. A total of 13 patients had endpoint events, including 3 patients (8.8%) in theobservation group and 10 patients (29.4%) in the control group. The 2-year DFS rate and 3-year DFS rate of the observation group and the control group were 97% vs. 71% and 89% vs. 71% respectively.The median DFS was undefined in the observation group. The median DFS of control groups was 44.50 (24.51-64.49)months, P=0.014, HR=0.22(95%CI 0.06-0.81, P=0.023). 44.1% of the patients had targeted drugrelated adverse reactions, the main adverse reactions included rash and liver function, which were tolerable in most patients.

Postoperative EGFR-TKIs therapy can prolong the survival time and reduce the risk of recurrence in patients with EGFR-positive IA stage invasive lung adenocarcinoma.